Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice

被引:35
作者
Edmeads, J
Láinez, JM
Brandes, JL
Schoenen, J
Freitag, F
机构
[1] Univ Toronto, Dept Med, Toronto, ON, Canada
[2] Hosp Clin Gen Univ, Neurol Serv, Valencia, Spain
[3] Neurol Grp, Nashville, TN USA
[4] CHR Citadelle, Liege, Belgium
[5] Columbus Hosp, Catholic Hlth Partners, Diamond Headache Clin, Chicago, IL USA
[6] Columbus Hosp, Catholic Hlth Partners, Diamond Headache Inpatient Treatment Unit, Chicago, IL USA
[7] Finch Univ Hlth Sci Chicago Med Sch, Chicago, IL USA
[8] Midwestern Univ, Coll Osteopath Med, Chicago, IL USA
关键词
D O I
10.1212/WNL.56.suppl_1.S29
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Migraine is not always well managed in clinical practice, often being under-diagnosed and undertreated. As a result, many sufferers never consult a physician or lapse from care after physician contact. Although most migraine care is provided by general practitioners, others, including specialists, emergency room physicians, pharmacists, and alternative practitioners, may also be involved. A method of standardizing clinical information about migraine is essential for coordinated, logical, and systematic care. The impact of migraine on the patient is an important clinical parameter but one that is seldom inquired about, perhaps because it exhibits such marked variability among and within individuals. Headache-related disability can be an objective and measurable index of this impact. The Migraine Disability Assessment (MIDAS) Questionnaire is a simple and validated instrument with potential for use in clinical practice, research, and public health. It can improve communication between patients and health-care professionals regarding the impact of migraine which, in turn, allows tailoring of the intensity of treatment to the severity of the illness. Changes in the MIDAS score may serve as an end point in assessing treatment efficacy. In populations, MIDAS scores may indicate the burden of migraine in the community and spark public health initiatives to improve management.
引用
收藏
页码:S29 / S34
页数:6
相关论文
共 41 条
[21]   METHODOLOGY OF CLINICAL-TRIALS OF SUMATRIPTAN IN MIGRAINE AND CLUSTER HEADACHE [J].
PILGRIM, AJ .
EUROPEAN NEUROLOGY, 1991, 31 (05) :295-299
[22]   IMPACT OF HEADACHE ON SICKNESS ABSENCE AND UTILIZATION OF MEDICAL-SERVICES - A DANISH POPULATION STUDY [J].
RASMUSSEN, BK ;
JENSEN, R ;
OLESEN, J .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1992, 46 (04) :443-446
[23]  
Richard A, 1999, SEM HOP PARIS, V75, P440
[24]   Prevalence of migraine in Japan: A nationwide survey [J].
Sakai, F ;
Igarashi, H .
CEPHALALGIA, 1997, 17 (01) :15-22
[25]  
Sawyer J, 1998, NEUROLOGY, V50, pA433
[26]  
Slater ND, 1999, NEUROLOGY, V52, pA209
[27]   Headaches and face pains as a manifestation of Munchausen syndrome [J].
Solomon, S ;
Lipton, RB .
HEADACHE, 1999, 39 (01) :45-50
[28]  
STANG PE, 1994, NEUROLOGY, V44, P47
[29]   THE DIAGNOSIS OF HEADACHE IN PRIMARY-CARE - FACTORS IN THE AGREEMENT OF CLINICAL AND STANDARDIZED DIAGNOSES [J].
STANG, PE ;
VONKORFF, M .
HEADACHE, 1994, 34 (03) :138-142
[30]   An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score [J].
Stewart, WF ;
Lipton, RB ;
Whyte, J ;
Dowson, A ;
Kolodner, K ;
Liberman, JN ;
Sawyer, J .
NEUROLOGY, 1999, 53 (05) :988-994